Estudio retrospectivo sobre la efectividad y seguridad de la pauta antibiótica reducida a 5-7 días en la faringoamigdalitis aguda estreptocócica comparada con la pauta clásica de 10 días / Retrospective study on the effectiveness and safety of the shortened 5- to 7-day antibiotic regimen for acute streptococcal pharyngotonsillitis compared to the classic 10-day regimen

Introducción: El tratamiento antibiótico clásico de la faringoamigdalitis aguda estreptocócica es una pauta de 10 días; sin embargo, la aparición de resistencias antibióticas induce a explorar pautas más cortas. Material y métodos: Seleccionamos a aquellos pacientes diagnosticados de faringoamigdalitis aguda estreptocócica en 2 cupos de pediatría de un centro de salud entre junio de 2016 y abril de 2020. Se compararon los resultados de aquellos que recibieron tratamiento 8-10 días con el de aquellos que lo recibieron 5-7 días. Resultados: Se analizaron 350 episodios (252 pacientes). El 64% recibieron tratamiento durante 8-10 días (grupo 1) y el 36% durante 5-7 días (grupo 2). No se observaron diferencias significativas en la aparición de faringoamigdalitis aguda estreptocócica o escarlatina los 3 meses posteriores (OR 0,97; IC 95%: 0,46-2,03), con una proporción similar en ambos grupos (9,8 vs. 9,5%). Sin diferenciar el tipo de infección (faringoamigdalitis aguda estreptocócica, escarlatina u otro tipo de infección streptocócica), se observaron resultados similares (OR 0,81; IC 95%: 0,41-1,59) con el 13,4% en el grupo 1 y el 11,1% en el 2. Respecto a la aparición de reacciones adversas medicamentosas recogidas en la historia clínica, fue de 2,7% en el grupo 1 y 0,8% en el 2 (OR 0,29; IC 95%: 0,04-2,44). Conclusiones: Según nuestra experiencia, la pauta antibiótica corta (5-7 días) en faringoamigdalitis aguda estreptocócica no es menos efectiva ni más insegura que la clásica pauta de 10 días. (AU)

Introduction: Antibiotherapy regimens for management of acute streptococcal pharyngitis traditionally last 10 days, but the development of resistance to different antimicrobials has motivated the exploration of shorter courses. Material and methods: We selected patients given a diagnosis of streptococcal pharyngitis in 2 paediatric caseloads of one primary care centre between June 2016 and April 2020. We compared outcomes in patients treated with 8- to 10-day courses versus 5- to 7-day courses. Results: The analysis included 350 care episodes (252 patients). Sixty-four percent were managed with 8- to 10-day courses of antibiotherapy (group 1) and 36% with 5- to 7-day courses (group 2). There were no significant differences in the incidence of streptococcal pharyngitis or scarlet fever in the 3 months that followed (OR, 0.98; 95% CI: 0.46-2.03), with similar percentages in both groups (9.8 vs. 9.5%). Overall, without differentiating based on the type of infection (streptococcal pharyngitis, scarlet fever or other streptococcal infections), we found similar outcomes (OR, 0.81; 95% CI: 0.41-1.59): 13.4% in group 1 and 11.1% in group 2. We also found no differences in the frequency of adverse events documented in the health records (OR, 0.29; 95% CI: 0.04-2.44): 2.7% in group 1 and 0.8% in group 2. Conclusions: In our experience, a shorter antibiotic course (5-7 days) is not less effective or more unsafe for management of acute streptococcal pharyngitis than the traditional 10-day course. (AU)

Retrospective study on the effectiveness and safety of the shortened 5- to 7-day antibiotic regimen for acute streptococcal pharyngotonsillitis compared to the classic 10-day regimen.

INTRODUCTION: Antibiotherapy regimens for management of acute streptococcal pharyngitis traditionally last 10 days, but the development of resistance to different antimicrobials has motivated the exploration of shorter courses. MATERIAL AND METHODS: We selected patients given a diagnosis of streptococcal pharyngitis in 2 paediatric caseloads of 1 primary care centre between June 2016 and April 2020. We compared outcomes in patients treated with 8- to 10-day courses versus 5- to 7-day courses. RESULTS: The analysis included 350 care episodes (252 patients). Sixty-four percent were managed with 8- to 10-day courses of antibiotherapy (group 1) and 36% with 5- to 7-day courses (group 2). There were no significant differences in the incidence of streptococcal pharyngitis or scarlet fever in the 3 months that followed (OR, 0.98; 95% confidence interval [CI], 0.46-2.03), with similar percentages in both groups (9.8% vs 9.5%). Overall, without differentiating based on the type of infection (streptococcal pharyngitis, scarlet fever or other streptococcal infections), we found similar outcomes (OR, 0.81; 95% CI, 0.41-1.59): 13.4% in group 1 and 11.1% in group 2. We also found no differences in the frequency of adverse events documented in the health records (OR, 0.29; 95% CI, 0.04-2.44): 2.7% in group 1 and 0.8% in group 2. CONCLUSIONS: In our experience, a shorter antibiotic course (5-7 days) is not less effective or more unsafe for management of acute streptococcal pharyngitis than the traditional 10-day course.

Hiperplasia endotelial papilar intravascular en la región supraclavicular / Intravascular papillary endothelial hyperplasia in the supraclavicular region

La hiperplasia endotelial papilar intravascular (IPEH) es una lesión vascular benigna poco frecuente que se presenta habitualmente como una neoformación subcutánea eritemato-violácea inespecífica. El estudio histopatológico, necesario para el diagnóstico de confirmación, muestra proliferación papilar de células endoteliales asociada con material trombótico. La IPEH puede simular otras lesiones como el angiosarcoma, por lo que el diagnóstico correcto de esta entidad es esencial para evitar tratamientos agresivos. La resección con márgenes amplios suele ser suficiente

Intravascular papillary endothelial hyperplasia (IPEH) is a rare benign vascular lesion that usually presents as a nonspecific erythematous-violaceous subcutaneous neoformation. The histopathological study, necessary for the confirmatory diagnosis, shows papillary proliferation of endothelial cells associated with thrombotic material. IPEH can simulate other lesions such as angiosarcoma, so the correct diagnosis of this entity is essential to avoid aggressive treatments. The resection with wide margins is usually enough